First Week Of MACK January 2014 Options Trading

Investors in Merrimack Pharmaceuticals Inc. ( MACK) saw new options begin trading this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MACK options chain for the new January 2014 contracts and identified the following put contract of particular interest.

The put contract at the $2.50 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $2.50, but will also collect the premium, putting the cost basis of the shares at $2.35 (before broker commissions). To an investor already interested in purchasing shares of MACK, that could represent an attractive alternative to paying $2.64/share today.

Because the $2.50 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 6.00% return on the cash commitment, or 36.50% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Merrimack Pharmaceuticals Inc., and highlighting in green where the $2.50 strike is located relative to that history:

Loading+chart++2013+TickerTech.com

The implied volatility in the put contract example above is 82%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $2.64) to be 72%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.

null

If you liked this article you might like

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

Verastem Shares Are Exploding 50% -- Here's Why

Verastem Shares Are Exploding 50% -- Here's Why

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers